Phathom Pharmaceuticals (PHAT) Revenue & Revenue Breakdown
Phathom Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$682.00K
Latest Revenue (Q)
$1.91M
Phathom Pharmaceuticals Revenue by Period
Phathom Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $682.00K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Phathom Pharmaceuticals generated $682.00K in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Phathom Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.91M | 180.35% |
| 2023-12-31 | $682.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Phathom Pharmaceuticals generated $1.91M in revenue during Q1 2024, up 180.35% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Phathom Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| KNSA | Kiniksa Pharmaceuticals | $270.26M | $112.21M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| VECT | VectivBio | $27.34M | $676.00K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| PHAT | Phathom Pharmaceuticals | $682.00K | $1.91M |
| KRTX | Karuna Therapeutics | $654.00K | - |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| AVRO | AVROBIO | - | - |
| CNSP | CNS Pharmaceuticals | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| IMMX | Immix Biopharma | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
PHAT Revenue FAQ
What is Phathom Pharmaceuticals’s yearly revenue?
Phathom Pharmaceuticals's yearly revenue for 2023 was $682K, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. PHAT's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Phathom Pharmaceuticals’s quarterly revenue?
Phathom Pharmaceuticals's quarterly revenue for Q1 2024 was $1.91M, a 180.35% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $682K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). PHAT's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Phathom Pharmaceuticals’s revenue growth rate?
Phathom Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.